Do low omega-3 levels impair inflammation resolution and keep CRP elevated?

Omega-3 fatty acids, specifically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are critical for the active termination of inflammation. Research confirms that these fatty acids serve as essential precursors to a class of molecules known as specialized pro-resolving mediators (SPMs).

Clinical and effectiveness evidence

Meta-analyses and randomized controlled trials consistently demonstrate that omega-3 supplementation reduces systemic inflammatory markers, including C-reactive protein (CRP).

• In populations with elevated baseline inflammation (e.g., hemodialysis patients, smokers, or those with metabolic conditions), doses of ≥2 g/day of EPA/DHA typically lead to significant reductions in high-sensitivity CRP (hs-CRP).
• Cross-sectional data show that a low Omega-3 Index (typically <4%) is associated with higher systemic CRP levels and a failure to transition from acute to resolved inflammation.

Mechanistic explanations

Inflammation resolution is an active biochemical process, not a passive "fading away" of signals.

• Precursor Role: EPA and DHA are oxygenated by enzymes like 15-lipoxygenase (15-LOX) to produce resolvins, protectins, and maresins.
• Active Resolution: Unlike traditional anti-inflammatories that merely block pathways, SPMs bind to specific G-protein coupled receptors (such as ChemR23 and ALX/FPR2) to signal the "off-switch."
• Immune Clearance: These mediators actively stop further neutrophil infiltration and enhance "efferocytosis"—the process where macrophages clear away dead cells and debris.
• Substrate Scarcity: When omega-3 status is low, the body lacks the necessary building blocks to produce these SPMs, leading to "failed resolution" where the immune response remains stuck in a pro-inflammatory state.

Bottom line

Low omega-3 status limits the body's ability to produce the SPMs required to actively terminate inflammation. This deficiency contributes to a "failed resolution" phenotype, which manifests clinically as persistently elevated inflammatory markers like C-reactive protein.